Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protagenic TherapeuticsPTIX +8.02%22 Quick Ratio is 0.34 as of Dec. 2025, which is 89% below its 10-year median of 3.04. GuruFocus rates PTIX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Protagenic Therapeutics ranks worse than 92.27% on this metric.
Protagenic Therapeutics (OTCPK:PTIX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Protagenic Therapeutics Quick Ratio Related Terms
Protagenic Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Protagenic Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protagenic Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Protagenic Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Protagenic Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protagenic Therapeutics (PTIX) has a Quick Ratio of 0.34 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Protagenic Therapeutics and its competitors. This is 89% below median its historical median of 3.04. Over the past decade, Protagenic Therapeutics' Quick Ratio has ranged from 0.29 to 20.00. According to the industry distribution chart, Protagenic Therapeutics ranks #1302 out of 1411 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Protagenic Therapeutics' Quick Ratio too high?
Protagenic Therapeutics' current Quick Ratio of 0.34 is 89% below median its 10-year median of 3.04. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 20.00. The Biotechnology industry median Quick Ratio is 3.57. Protagenic Therapeutics' value of 0.34 is 90.5% below this industry median. Based on the distribution chart, Protagenic Therapeutics ranks #1302 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protagenic Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Protagenic Therapeutics' Quick Ratio compare to CERO and CYTOF?
According to the Biotechnology industry distribution chart, Protagenic Therapeutics ranks #1302 out of 1411 companies for Quick Ratio. This places Protagenic Therapeutics in the lower half of its industry. The industry median Quick Ratio is 3.57. Protagenic Therapeutics' value of 0.34 is 90.5% below this benchmark. Historically, Protagenic Therapeutics' own Quick Ratio has ranged from 0.29 to 20.00 over the past decade. While the company's 10-year median is 3.04 vs. the industry median of 3.57, Protagenic Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protagenic Therapeutics's current Quick Ratio of 0.34 is 90.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Protagenic Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protagenic Therapeutics's current Quick Ratio is 0.34, which is 89% below median its own 10-year median of 3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagenic Therapeutics stock overvalued right now?
Protagenic Therapeutics (PTIX) has a current Quick Ratio of 0.34. The current Quick Ratio is 0.34, which is 89% below median its 10-year median of 3.04 and 90.5% below the Biotechnology industry median of 3.57. Protagenic Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Protagenic Therapeutics (PTIX), the current Quick Ratio is 0.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
22GF Score
Get the complete analysis for PTIX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTIX has been successfully added to your 
